ADC Therapeutics (ADCT) Cost of Revenue (2021 - 2026)
ADC Therapeutics (ADCT) posted quarterly Cost of Revenue of $3.5 million for Q1 2026, up 68.22% year-on-year from $2.1 million in Q1 2025, and up 188.44% on a QoQ basis from $1.2 million in Q3 2025.
ADC Therapeutics (ADCT) Cost of Revenue (2021 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Cost of Revenue for 6 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | ADC Therapeutics | 174.95 Mn | -56.06 Mn | 17.38 Mn | 3.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.47 Mn |
| Mar 31, 2026 | 3.47 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 836,000.00 |
| Jun 30, 2025 | 836,000.00 |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Sep 30, 2024 | 851,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Jun 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Sep 30, 2023 | 366,000.00 |
| Sep 30, 2023 | 366,000.00 |
| Jun 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | 590,000.00 |
| Mar 31, 2023 | 590,000.00 |